Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.57 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.43 |
| ▸ | TMPRSS2 | O15393 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2989688 | 0.93 | HDAC6 (0.58) | ESR2HDAC6HDAC8NR1H2HDAC1 | |
| SCHEMBL2120817 | 0.93 | HDAC6 (0.54) | ESR2HDAC6HDAC8NR1H2HDAC1 | |
| SCHEMBL24038582 | 0.90 | HDAC1 (0.59) | ESR2HDAC6HDAC8NR1H2HDAC1 | |
| SCHEMBL30090292 | 0.90 | HDAC1 (0.59) | ESR2HDAC6HDAC8NR1H2HDAC1 | |
| SCHEMBL14063092 | 0.84 | ESR2 (0.69) | ESR2HDAC6HDAC8NR1H2HDAC1 | |
| SCHEMBL30301758 | 0.84 | ESR2 (0.69) | ESR2HDAC6HDAC8NR1H2HDAC1 | |
| SCHEMBL3024823 | 0.84 | ESR2 (0.69) | ESR2HDAC6HDAC8NR1H2HDAC1 | |
| SCHEMBL306991 | 0.84 | ESR2 (0.72) | ESR2HDAC6HDAC8NR1H2HDAC1 | |
| SCHEMBL1365145 | 0.84 | ESR2 (0.72) | ESR2HDAC6HDAC8NR1H2HDAC1 | |
| SCHEMBL29406723 | 0.84 | ESR2 (0.72) | ESR2HDAC6HDAC8NR1H2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2958913-B1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG CHEMICAL LTD (KR) | 2018-10-03 | — | — | EP | disclosed |
| US-9540362-B2 | Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent | LG LIFE SCIENCES LTD. (KR) | 2017-01-10 | — | — | US | disclosed |
| US-20150376173-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD. (KR) | 2015-12-31 | — | — | US | disclosed |
| EP-2958913-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG Life Sciences Ltd. (KR) | 2015-12-30 | — | — | EP | disclosed |
| WO-2014129796-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD. (KR) | 2014-08-28 | — | — | WO | disclosed |
| US-20120101083-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2443110-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | Glaxo Group Limited (GB) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010146105-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376173-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | S1PR1, S1PR2, S1PR5 | ESR2 2100/4885HDAC6 3295/4885HDAC8 3024/4885 |
| US-20120101083-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | S1PR1, S1PR2, S1PR3 | ESR2 443/4885HDAC6 2223/4885HDAC8 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.